$GLENMARK

Glenmark Pharmaceuticals Ltd. reported its financial results for the quarter ending March 2026, revealing a mixed performance. The company's net sales for this quarter stood at ₹3,770.59 crores, reflecting a sequential decline of 3.33% from the previous quarter, although this figure represents a year-on-year increase of 15.80%. The net profit for the same period was ₹301.41 crores, which indicates a sequential decrease of 25.25%, but a substantial year-on-year growth of 6,381.94% from a very low base in the previous year. The operating margin for Q4 FY26 contracted to 20.28%, down from 22.37% in the prior quarter, which is attributed to the unwinding of exceptional profitability seen in Q3 FY26 and rising employee costs. Despite this sequential moderation, the operating margin remains significantly higher than the 17.42% recorded in Q4 FY25, suggesting ongoing operational improvements on an annual basis. Glenmark's return on capital employed (ROCE) reached an impressive 40.16% for the half-year period, marking the highest level in recent years and indicating strong capital productivity. The balance sheet remains robust, with a net debt-to-equity ratio of -0.06, positioning the company as a net cash entity, which enhances its financial flexibility. Overall, while Glenmark Pharmaceuticals experienced sequential declines in key financial metrics, the year-on-year comparisons indicate substantial growth from a depressed base, reflecting a complex operational landscape. The company saw an adjustment in its evaluation, reflecting these dynamics in its financial performance.